acute-myeloid-leukemia-therapeutics-market
Published

October 2017

Global Acute Myeloid Leukemia Therapeutics Market – Growth, Trends and Forecasts (2017 – 2022)

Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license

 Acute Myeloid Leukemia Therapeutics Market 

The market was estimated at USD XX million in 2015 and is expected to reach USD XX million by 2021, growing at a CAGR of X% during the forecast period 2016 to 2021.

As per the American Cancer Society, it is estimated that 19,950 new cases of acute myeloid leukemia (AML) are expected, in 2016; most of the cases are in adults. Due to AML, nearly 10,430 deaths are expected in 2016 in the United States itself. The National Cancer Institute states that only 26.6% diagnosed cases survive for five years. New drug launches and targeted therapy trends are propelling the growth of the market. The increasing access to drugs in the emerging economies, due to these countries’ government initiatives, and increasing spending on the development of healthcare facilities in these regions are fueling the growth of the market.

Market Dynamics

Key factors propelling the growth of the market, globally, are -

  • High incidence and prevalence rate of acute myeloid leukemia
  • Increasing expenditure on healthcare
  • Increasing investments in R&D
  • Advancement in pharmacology and molecular biology, promoting drug development

The key factors turning out to be constraints for this market are -

  • Complications due to chemotherapy
  • Stringent regulatory guidelines

Market Segmentation

The market has been segmented based on chemotherapeutics and geography. The chemotherapeutics segment includes cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy and others. The anthracycline drugs have been further segmented into Daunomycin, Idarubicin, and Mitoxantrone. The tyrosine kinase inhibitors include Dasatinib and Imatinib.

Geographically, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.

The key players in this market are

  • Celegene Corporation
  • Novartis AG
  • Clavis Pharma
  • Eisai Co. Ltd.
  • Genzyme Corporation
  • Cephalon Inc.
  • Ambit Biosciences Corporation
  • Bristol Myer Squibb

What the Report Offers

  • Market definition, along with identification of key drivers and restraints for the market.
  • Market analysis with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
  • A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
  • An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
RELATED REPORTS
No related reports available.
Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license
Our Clients Include View All

Looking to Customize Report?